Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of the Efficacy and Safety of Vosoritide in Patients with Achondroplasia
IRCT20211218053442N4Phase 2Recruiting
- Sponsor
- Zistdaru Danesh
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of vosoritide in achondroplasia (ACH), sponsored by Zistdaru Danesh. Started Aug 2026; status: recruiting.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on IRCT20211218053442N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20211218053442N4.